Braveheart Bio, Inc. (BRVE)
Braveheart Bio, Inc. (BRVE) tracked by StreetAlpha. It last closed at $18.78 on Nov 17, down 3.64% on the day. BRVE reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 4 analysts is $45.25 (+140.9% from the last close), with a high of $48.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on BRVE in the past 90 days. The average target is $45.25, with a high of $48.00 and a low of $40.00, compared with the last close of $18.78.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 31 | Goldman Sachs | Initiated | Buy | $48 |
| Aug 31 | Jefferies | Initiated | Buy | $48 |
| Aug 31 | Cantor Fitzgerald | Initiated | Buy | $40 |
| Aug 31 | Stifel | Initiated | Buy | $45 |
Technical Analysis
The stock is 9% below its 20 day and 16% below its 50 day average. Momentum is weak (RSI 41). The nearest support is the Pivot at $18.68, and the nearest resistance the Pivot R1 at $19.56.
| RSI (14) | 41.25 | Middle of its range | Neutral |
| MACD | -0.59 | Below its signal line | Bearish |
| Stochastic | 47.1 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -62.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -113.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.2% | Change over 10 sessions | Bearish |
| ATR (14) | $1.63 | Typical daily range, 8.7% of price |
What happened before
See how BRVE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in BRVE in the last 90 days.
BRVE Institutional Ownership
Full report →- ▲64 buying vs 0 selling
- ●Shares held by funds +0.0%
- ●Funds holding +64
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 64 | – | – |
| In funds' top 10 | 5 | – | – |
| Held by funds | – | – | – |
| New / increased | 64 / 0 | – | – |
| Reduced / sold out | 0 / 0 | – | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BRVE is in one of them and how their past BRVE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BRVE in an article yet. Here's the latest on the wider market.

